It is a non-randomised, single-arm, open-label, multi-centre, diagnostic clinical trial of 64 Cu-SAR-bisPSMA positron emission tomography (PET) in participants with rising or detectable prostate ...

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared ...

A new diagnostic which could transform the detection of cancer is about to enter a pivotal, large-scale trial. Owlstone Medical’s Breath Biopsy is a novel device which promises to detect cancer ...

Ultrasound was not performed in 39% of D-dimer patients. In this trial, a diagnostic strategy that involved D-dimer testing and selective ultrasonography performed as well as a strategy of ...

AOA Dx Inc. closed an oversubscribed $17 million seed round to expand the clinical trial for its ovarian cancer diagnostic test, build out new lab facilities and explore applications of its ...

is pleased to announce the completion of recruitment for the Phase I PROPELLER diagnostic trial evaluating its 64 Cu-SAR-bisPSMA product candidate in patients with untreated, confirmed prostate ...

The trial will not only provide clinical data ... expects the partnership with INTER-PSY to support adoption of its platform as a diagnostic tool within the autism diagnostic community in Europe.

The trial’s results suggest that emphasizing the first line of treatment and giving the most effective therapy straight after diagnosis is particularly important for patients with high-risk ...

It is a non-randomised, single-arm, open-label, multi-centre, diagnostic clinical trial of 64 Cu-SAR-bisPSMA positron emission tomography (PET) in participants with rising or detectable ...